Tim Anderson
Stock Analyst at B of A Securities
(4.05)
# 466
Out of 4,840 analysts
33
Total ratings
75%
Success rate
6.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $575 → $547 | $596.85 | -8.35% | 2 | Apr 17, 2025 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $171 → $159 | $152.61 | +4.19% | 5 | Apr 10, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $22 → $26 | $10.01 | +159.74% | 2 | Mar 27, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $116 → $126 | $106.74 | +18.04% | 2 | Mar 5, 2025 | |
| AMGN Amgen | Maintains: Underperform | $275 → $294 | $271.90 | +8.13% | 4 | Mar 5, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $223 | $182.54 | +22.17% | 5 | Mar 4, 2025 | |
| MTSR Metsera | Initiates: Buy | $38 | $28.05 | +35.50% | 1 | Feb 25, 2025 | |
| MRNA Moderna | Maintains: Underperform | $41 → $34 | $26.72 | +27.25% | 2 | Feb 11, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $118 → $112 | $77.84 | +43.88% | 4 | Feb 5, 2025 | |
| PFE Pfizer | Reinstates: Neutral | $29 | $23.04 | +25.87% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $63 | $47.03 | +33.96% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $126.30 | +40.93% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $997 | $715.20 | +39.40% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $112.50 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $69.95 | - | 1 | Sep 22, 2017 |
Regeneron Pharmaceuticals
Apr 17, 2025
Maintains: Underperform
Price Target: $575 → $547
Current: $596.85
Upside: -8.35%
Johnson & Johnson
Apr 10, 2025
Maintains: Neutral
Price Target: $171 → $159
Current: $152.61
Upside: +4.19%
Aardvark Therapeutics
Mar 27, 2025
Maintains: Buy
Price Target: $22 → $26
Current: $10.01
Upside: +159.74%
Gilead Sciences
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $106.74
Upside: +18.04%
Amgen
Mar 5, 2025
Maintains: Underperform
Price Target: $275 → $294
Current: $271.90
Upside: +8.13%
AbbVie
Mar 4, 2025
Maintains: Neutral
Price Target: $200 → $223
Current: $182.54
Upside: +22.17%
Metsera
Feb 25, 2025
Initiates: Buy
Price Target: $38
Current: $28.05
Upside: +35.50%
Moderna
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $26.72
Upside: +27.25%
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $118 → $112
Current: $77.84
Upside: +43.88%
Pfizer
Dec 10, 2024
Reinstates: Neutral
Price Target: $29
Current: $23.04
Upside: +25.87%
Dec 10, 2024
Reinstates: Neutral
Price Target: $63
Current: $47.03
Upside: +33.96%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $126.30
Upside: +40.93%
Dec 10, 2024
Reinstates: Buy
Price Target: $997
Current: $715.20
Upside: +39.40%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $112.50
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $69.95
Upside: -